Tibet Cheezheng Tibetan Medicine Co., Ltd. (SHE:002287)
China · Delayed Price · Currency is CNY 19.86
-0.81 (-3.92%)
Aug 21, 2026, 3:04 PM CST
SHE:002287 Revenue
Tibet Cheezheng Tibetan Medicine had revenue of 572.72M CNY in the quarter ending June 30, 2026, a decrease of -25.82%. This brings the company's revenue in the last twelve months to 2.22B, down -11.36% year-over-year. In the year 2025, Tibet Cheezheng Tibetan Medicine had annual revenue of 2.42B with 3.34% growth.
Revenue (ttm)
2.22B
Revenue Growth
-11.36%
P/S Ratio
5.07
Revenue / Employee
692.77K
Employees
3,203
Market Cap
11.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.42B | 78.04M | 3.34% |
| Dec 31, 2024 | 2.34B | 292.82M | 14.32% |
| Dec 31, 2023 | 2.05B | 363.07K | 0.02% |
| Jan 1, 2023 | 2.04B | 274.30M | 15.49% |
| Jan 1, 2022 | 1.77B | 285.43M | 19.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Inner Mongolia Furui Medical Science | 1.63B |
| Nanjing Vazyme Biotech | 1.41B |
| Shanghai Medicilon | 1.26B |
| Hualan Biological Vaccine | 1.20B |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |
| Mabwell (Shanghai) Bioscience | 745.32M |